Analysis and data insight, BioWorld Asia
Analysis and data insight, BioWorld Asia RSS Feed RSS

Injection syringes
Biopharma regulatory actions and approvals June 2024

Eylea, Neupogen, Stelara biosimilars among 28 FDA nods in June

July 23, 2024
By Amanda Lanier
The U.S. FDA approved 28 new drugs in June, marking the third-highest month in BioWorld’s records, following March 2024’s 30 approvals and June 2020's 29 approvals, and a significant increase from May’s 11 FDA drug approvals. For context, the FDA approved an average of around 16 drugs per month in 2023, 12.5 per month in 2022, and 17 per month in both 2021 and 2020.
Read More
Biomap signing ceremony

Biomap sets new global ‘biocomputing’ hub in Hong Kong

July 16, 2024
By Marian (YoonJee) Chu
Silicon Valley-based Biomap is setting up a new global biocomputing innovation hub, dubbed Biomap Innohub, in Hong Kong as the local government ramps up investment to build supercomputing prowess, Vicky Qu, senior vice president of Biomap, told BioWorld. The goal is to accelerate novel drug product development and commercialization with biocomputing.
Read More
Dollar sign thermometer
Biopharma financings June 2024

First half of 2024 sees biopharma financings nearing full-year 2023 total

July 9, 2024
By Amanda Lanier
Biopharma financings reached $70.09 billion in the first half of 2024, a 129% increase from the $30.57 billion raised in the first half of 2023. At more than $70 billion, this year's financings are already approaching the full-year total of $70.97 billion for 2023. June saw $7.57 billion in total financings, a decrease from $9.15 billion in May.
Read More
Clinical data illustration
Biopharma clinical updates May 2024

May’s 298 clinical trial updates led by Astrazeneca, Hutchmed and Novartis

July 2, 2024
By Amanda Lanier
In May 2024, BioWorld covered 298 updates across phase I-III clinical trials, surpassing March (261), February (236) and January (252), though falling short of April’s high of 323. Additionally, at the end of May BioWorld revised its reporting criteria for clinical trial updates, focusing mainly on data readouts and excluding trial initiations, enrollment changes and initial patient dosing, thereby impacting the update count relative to prior months.
Read More
FDA Approved stamp with pills, bottle, blister pack
Biopharma regulatory actions and approvals May 2024

Two Eylea biosimilars among 11 FDA drug approvals in May

June 25, 2024
By Amanda Lanier
In May, the U.S. FDA approved 11 new drugs, a significant drop from the 26 approvals in April, which was the sixth-highest monthly total since 2016. This also falls short of March’s record-setting 30 approvals, the highest number recorded by BioWorld.
Read More
3D illustration demonstrating antibody-drug conjugate.

Companies to Watch: Seven ADC companies under the radar

June 25, 2024
By Lee Landenberger
The annual Companies to Watch report, which was just released, looks closely at seven companies flying under the radar that are developing antibody-drug conjugates (ADCs) for treating cancer. Companies examined in the new report are Adcendo ApS, Araris Biotech AG, Go Therapeutics Inc., Heidelberg Pharma AG, Pheon Therapeutics Ltd., Tallac Therapeutics Inc. and Tubulis GmbH.
Read More
Biopharma deals May 2024

May biopharma deals hit $18.76B, up 23% from April

June 18, 2024
By Amanda Lanier
Biopharma deal value surged in May to $18.76 billion, up 23% from April's $15.28 billion. This increase follows March’s $8.29 billion and February’s $7.76 billion, although represents a decline from January’s $27.9 billion. The monthly average for 2024 stands at $15.64 billion, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As rose to $4.75 billion in May, an increase from April’s $1.33 billion, which was the lowest figure in nearly a year.
Read More